Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota

From BugSigDB
Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/31
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Stewardson AJ, Gaïa N, François P, Malhotra-Kumar S, Delémont C, Martinez de Tejada B, Schrenzel J, Harbarth S, Lazarevic V
Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Year
2015
Keywords:
Antibiotics, ecologic damage, microbiomics, microbiota, urinary tract infection
Recent treatment guidelines for uncomplicated urinary tract infections (UTIs) discourage fluoroquinolone prescription because of collateral damage to commensal microbiota, but the ecologic impact of alternative agents has not been evaluated by culture-free techniques. We prospectively collected faecal samples at three time points from ambulatory patients with UTIs treated with ciprofloxacin or nitrofurantoin, patients not requiring antibiotics and household contacts of ciprofloxacin-treated patients. We described changes in gut microbiota using a culture-independent approach based on pyrosequencing of the V3-V4 region of the bacterial 16S rRNA gene. All groups were similar at baseline. Ciprofloxacin had a significant global impact on the gut microbiota whereas nitrofurantoin did not. The end of ciprofloxacin treatment correlated with a reduced proportion of Bifidobacterium (Actinobacteria), Alistipes (Bacteroidetes) and four genera from the phylum Firmicutes (Faecalibacterium, Oscillospira, Ruminococcus and Dialister) and an increased relative abundance of Bacteroides (Bacteroidetes) and the Firmicutes genera Blautia, Eubacterium and Roseburia. Substantial recovery had occurred 4 weeks later. Nitrofurantoin treatment correlated with a reduced relative proportion of the genus Clostridium and an increased proportion of the genus Faecalibacterium. This study supports use of nitrofurantoin over fluoroquinolones for treatment of uncomplicated UTIs to minimize perturbation of intestinal microbiota.

Experiment 1


Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/31

Curated date: 2021/09/17

Curator: Mmarin

Revision editor(s): LGeistlinger, Mmarin, WikiWorks, Victoria

Subjects

Location of subjects
Switzerland
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Antimicrobial agent antibiotic,antibiotics,Antibiotika,Antibiotikum,antibiotique,antimicrobial,antimicrobial agents,microbicide,microbicides,Antimicrobial agent,antimicrobial agent
Group 0 name Corresponds to the control (unexposed) group for case-control studies
baseline of the ciprofloxacin treated
Group 1 name Corresponds to the case (exposed) group for case-control studies
ciprofloxacin treated
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
UTI patients treated with ciprofloxacin 500mg twice daily
Group 0 sample size Number of subjects in the control (unexposed) group
10
Group 1 sample size Number of subjects in the case (exposed) group
10
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
2 months

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Roche454

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
Mann-Whitney (Wilcoxon)
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
unchanged
Chao1 Abundance-based estimator of species richness
unchanged
Simpson Estimator of species richness and species evenness: more weight on species evenness
unchanged

Signature 1

Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/31

Curated date: 2021/09/23

Curator: Mmarin

Revision editor(s): Mmarin, Claregrieve1

Source: Figure 3

Description: Differential microbial abundance between baseline (timepoint 1) and timepoint 2 in ciprofloxacin treated patients

Abundance in Group 1: decreased abundance in ciprofloxacin treated

NCBI Quality ControlLinks
Bifidobacteriaceae
Faecalibacterium
Oscillospira
Oscillospiraceae
Ruminococcus

Revision editor(s): Mmarin, Claregrieve1

Signature 2

Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/31

Curated date: 2021/09/23

Curator: Mmarin

Revision editor(s): Mmarin, Claregrieve1

Source: Figure 3

Description: Differential microbial abundance between baseline (timepoint 1) and timepoint 2 in ciprofloxacin treated patients

Abundance in Group 1: increased abundance in ciprofloxacin treated

NCBI Quality ControlLinks
Bacteroidaceae
Blautia
Clostridium
Eubacterium
Lachnospiraceae
Roseburia

Revision editor(s): Mmarin, Claregrieve1

Experiment 2


Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/31

Curated date: 2021/09/23

Curator: Mmarin

Revision editor(s): LGeistlinger, Mmarin, WikiWorks, Victoria

Differences from previous experiment shown

Subjects

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Antimicrobial agent antibiotic,antibiotics,Antibiotika,Antibiotikum,antibiotique,antimicrobial,antimicrobial agents,microbicide,microbicides,Antimicrobial agent,antimicrobial agent
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Baseline of the Nitrofurantoin treated
Group 1 name Corresponds to the case (exposed) group for case-control studies
Nitrofurantoin treated
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
UTI patients treated with nitrofurantoin macrocrystals 100mg twice daily

Lab analysis

Statistical Analysis

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
unchanged
Chao1 Abundance-based estimator of species richness
unchanged
Simpson Estimator of species richness and species evenness: more weight on species evenness
unchanged

Signature 1

Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/31

Curated date: 2021/09/23

Curator: Mmarin

Revision editor(s): Mmarin, Claregrieve1

Source: Figure 3

Description: Differential microbial abundance between baseline and post-treatment timepoints in nitrofurantoin treated group

Abundance in Group 1: decreased abundance in Nitrofurantoin treated

NCBI Quality ControlLinks
Clostridiaceae

Revision editor(s): Mmarin, Claregrieve1

Signature 2

Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/31

Curated date: 2021/09/23

Curator: Mmarin

Revision editor(s): Mmarin, Claregrieve1

Source: Figure 3

Description: Differential microbial abundance between baseline and post-treatment timepoints in nitrofurantoin treated group

Abundance in Group 1: increased abundance in Nitrofurantoin treated

NCBI Quality ControlLinks
Faecalibacterium

Revision editor(s): Mmarin, Claregrieve1

Experiment 6


Reviewed Marked as Reviewed by Claregrieve1 on 2022/11/3

Curated date: 2021/10/15

Curator: Mmarin

Revision editor(s): WikiWorks, LGeistlinger, Claregrieve1, Mmarin, Victoria

Differences from previous experiment shown

Subjects

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Antimicrobial agent , Urinary tract infection antibiotic,antibiotics,Antibiotika,Antibiotikum,antibiotique,antimicrobial,antimicrobial agents,microbicide,microbicides,Antimicrobial agent,antimicrobial agent,INFECTION, URINARY TRACT,TRACT, INFECTION OF URINARY,urinary tract infection,urinary tract infection (disease),Urinary tract infection
Group 0 name Corresponds to the control (unexposed) group for case-control studies
control group (timepoint 2)
Group 1 name Corresponds to the case (exposed) group for case-control studies
Ciprofloxacin treated group (timepoint 2)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
ciprofloxacin group at end of antibiotic treatment

Lab analysis

Statistical Analysis

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
unchanged
Chao1 Abundance-based estimator of species richness
unchanged
Simpson Estimator of species richness and species evenness: more weight on species evenness
unchanged

Signature 1

Reviewed Marked as Reviewed by Claregrieve1 on 2022/11/3

Curated date: 2021/10/15

Curator: Mmarin

Revision editor(s): Mmarin, Claregrieve1

Source: Table S2

Description: Differential microbial abundance between the control group and ciprofloxacin-treated group at timepoint 2

Abundance in Group 1: increased abundance in Ciprofloxacin treated group (timepoint 2)

NCBI Quality ControlLinks
Alistipes
Lachnospiraceae
Oscillospira
Parabacteroides
Porphyromonadaceae
Rikenellaceae
Roseburia
Ruminococcus
Veillonellaceae

Revision editor(s): Mmarin, Claregrieve1

Experiment 7


Reviewed Marked as Reviewed by Claregrieve1 on 2022/11/3

Curated date: 2021/10/15

Curator: Mmarin

Revision editor(s): WikiWorks, LGeistlinger, Claregrieve1, Mmarin, Victoria

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
controls (timepoint 2)
Group 1 name Corresponds to the case (exposed) group for case-control studies
nitrofurantoin treated group (timepoint 2)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
nitrofurantoin-treated group at end of treatment

Lab analysis

Statistical Analysis

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
unchanged
Chao1 Abundance-based estimator of species richness
unchanged
Simpson Estimator of species richness and species evenness: more weight on species evenness
unchanged

Signature 1

Reviewed Marked as Reviewed by Claregrieve1 on 2022/11/3

Curated date: 2021/10/15

Curator: Mmarin

Revision editor(s): Mmarin, Claregrieve1

Source: Table S2

Description: Differential microbial abundance between the control group and nitrofurantoin-treated group at timepoint 2

Abundance in Group 1: increased abundance in nitrofurantoin treated group (timepoint 2)

NCBI Quality ControlLinks
Alistipes
Bacteroidales
Bacteroidia
Bacteroidota
Faecalibacterium
Rikenellaceae

Revision editor(s): Mmarin, Claregrieve1